The Price of Survival: When Cancer Care Costs as Much as a Mortgage
AI-generated image · Bay Street Wire
For patients like James Howard, the latest breakthrough in pancreatic cancer treatment comes with a price tag that defies logic and threatens financial ruin.
When a life-saving prescription costs as much as a home down payment every single month, we aren't talking about healthcare anymore—we're talking about a predatory pricing crisis that's bankrupting the desperate.
As CBC News first reported, consider the case of James Howard. Diagnosed with pancreatic cancer in November 2025 in Vancouver, Howard's battle progressed to Stage 4 after chemotherapy failed. He found a glimmer of hope in daraxonrasib, a drug that received approval from the U.S. Food and Drug Administration (FDA) this past August. The problem? The drug is not yet approved in Canada. To access the treatment, Howard is paying roughly $90,000 Cdn (approximately $63,000 US) per month.
**OPINION:** This is not a sustainable model of care; it is a hostage situation where the ransom is the patient's own life.
According to reporting from CBC News, the drug—marketed as Rasonque—is produced by the California-based drug maker Revolution Medicines. The company set the annual launch price at $480,000 US ($675,000 Cdn), with a 30-day wholesale supply costing $40,000 US. In a statement to CBC News, Revolution Medicines argued that out-of-pocket costs vary based on insurance and treatment duration.
Medical professionals are sounding the alarm. Dr. Christopher Booth, a medical oncologist in Kingston, Ont., and health-services researcher at Queen's University, told CBC News that while pharmaceutical companies deserve to make money, corporate greed is now harming patients and health systems. He notes that daraxonrasib represents a significant medical advancement, with clinical trials showing it increased survival from less than seven months to roughly 13 and halted or reversed tumor progression in nearly a third of patients.
The mechanism driving these costs is rooted in the U.S. regulatory environment. Dr. Booth explains to CBC News that the U.S. operates in an ecosystem that essentially forbids government negotiation with pharmaceutical companies during most new drug launches, allowing manufacturers to set their own prices. While the 2022 Inflation Reduction Act slightly eased these rules, the trend remains upward. Data from the Boston-based Institute for Clinical and Economic Review (ICER) indicates the median net price for new drugs launched in the U.S. last year was over $250,000 US—a more than 35 percent increase from the $190,000 US median recorded three years prior.
For Canadians, the crisis is compounded by the gap between U.S. FDA approval and Health Canada regulatory approval. Until a drug is approved and funded domestically, patients are forced to choose between paying exorbitant sums out of pocket or foregoing potentially life-extending medication. As more than two dozen cancer specialists told CBC News, this trend is pushing the public health-care system toward a breaking point.